IFM Investors Pty Ltd Has $14.77 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

IFM Investors Pty Ltd grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,285 shares of the biopharmaceutical company's stock after buying an additional 1,935 shares during the quarter. IFM Investors Pty Ltd's holdings in Regeneron Pharmaceuticals were worth $14,768,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in REGN. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $28,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the period. Finally, Tompkins Financial Corp acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $2.74 during trading hours on Friday, hitting $545.00. 456,413 shares of the company's stock were exchanged, compared to its average volume of 905,431. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock has a market cap of $58.84 billion, a price-to-earnings ratio of 13.87, a price-to-earnings-growth ratio of 2.00 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock's 50-day moving average is $549.38 and its 200-day moving average is $625.94.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the business earned $9.55 EPS. The business's revenue for the quarter was down 3.7% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Analyst Upgrades and Downgrades

REGN has been the subject of several research analyst reports. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a research report on Monday, June 2nd. UBS Group reduced their price target on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a report on Thursday, June 5th. Royal Bank Of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research report on Friday, May 30th. Finally, Citigroup reduced their price objective on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $822.58.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.